Last reviewed · How we verify
Benzydamine Hydrochloride 0.15% Oral gel
Benzydamine Hydrochloride 0.15% Oral gel is a Small molecule drug developed by Minia University. It is currently FDA-approved.
Benzydamine Hydrochloride 0.15% Oral gel, marketed by Minia University, is an established product in the oral gel segment. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue stability. The primary risk lies in the lack of reported key trial results and revenue data, which may limit investor confidence and market competitiveness.
At a glance
| Generic name | Benzydamine Hydrochloride 0.15% Oral gel |
|---|---|
| Sponsor | Minia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Efficacy of Aloe-Vera el Versus Bezydamine Hydrochloride in the Prevention of Radiation Induced Oral Mucositis A Randamized Controlled Clinical Trial (PHASE4)
- Comparison Between the Effect of Aloe Vera and Benzydamine Hydrochloride Mouth Gel on Prevention of Pain and Progression of Radiation-induced Oral Mucositis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benzydamine Hydrochloride 0.15% Oral gel CI brief — competitive landscape report
- Benzydamine Hydrochloride 0.15% Oral gel updates RSS · CI watch RSS
- Minia University portfolio CI